The rationale behind these trials has been to study the impact of CD27 agonism alone as a T-cell co-stimulator as well as to determine if it functions in a synergistic manner in combination with checkpoint inhibitor therapy and cancer vaccines to improve antineoplastic response. This evidence concerns the gene CD27 and cancer.